◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
technica.bio / Polish Biotech Scene / Medicalgorithmics
Polish Biotech Scene

Medicalgorithmics

AI cardiac diagnostics · Arrhythmia monitoring

MarketGPW Main MarketWarsawAI-Driven Drug Discovery
Focus / modality
AI cardiac diagnostics
Lead asset
PocketECG · DeepRhythmAI
Type
Diagnostics / AI
Indication
Arrhythmia monitoring
Stage
Market
HQ
Warsaw
Capital tier
GPW Main Market
Backing
GPW

Overview

Pioneer of full-disclosure mobile cardiac telemetry (PocketECG) and DeepRhythmAI ECG algorithms used across the US and Europe.

What they do

Medicalgorithmics S.A. is a Warsaw Stock Exchange-listed Polish company specializing in AI-driven cardiac diagnostics for arrhythmia detection and heart-rhythm monitoring. It is best known for pioneering full-disclosure mobile cardiac telemetry through its PocketECG system and for its DeepRhythmAI (DRAI) family of deep-learning ECG-analysis algorithms, used in the US and Europe and in clinical drug trials for cardiac safety.

Lead program & status

The lead assets are PocketECG (remote, full-disclosure cardiac monitoring) and DeepRhythmAI for automated multichannel ECG analysis. DeepRhythmAI algorithms have been FDA-cleared in the US since 2022, and the company has announced FDA 510(k) clearance for a newer DeepRhythmAI version that supports both two-lead and single-lead (patch) configurations, broadening its applicability for arrhythmia detection. The technology is positioned to speed and improve the accuracy of ECG interpretation at scale across monitoring services.

Why it matters

Arrhythmias are common, episodic and easy to miss on short recordings. Full-disclosure telemetry plus validated AI analysis lets providers capture and interpret far more data with less manual reading burden, supporting earlier, more accurate diagnosis, an area where Medicalgorithmics has been an established international player.

FAQ

What is PocketECG?
PocketECG is Medicalgorithmics' full-disclosure mobile cardiac telemetry system for remote, continuous monitoring and diagnosis of heart-rhythm disorders, also used in cardiac-safety drug trials.
What is DeepRhythmAI?
DeepRhythmAI (DRAI) is Medicalgorithmics' set of deep-learning algorithms that automatically analyze ECG signals to detect arrhythmias; it has been FDA-cleared since 2022, with a newer version cleared supporting two-lead and single-lead inputs.
Where is Medicalgorithmics used?
Its PocketECG and DeepRhythmAI technologies are used across the United States and Europe by cardiac-monitoring services and in clinical research.

Technology

Medicalgorithmics works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.

Read the AI-Driven Drug Discovery brief →

Related companies

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.